Samiah Al-Zaidy

4.8k citations

26 papers · 1.8k indexed · 3 hit papers · h-index 15

Molecular Biology top 5%
Genetics top 5%
Genetics top 1%
Surgery top 10%
Cardiology and Cardiovascular Medicine top 10%

Co-authors: Jerry R. Mendell Louise R. Rodino‐Klapac Linda Lowes Lindsay N. Alfano Richard Shell Kelly J. Lehman Jacques P. Tremblay Barry J. Byrne
Topics: Neurogenetic and Muscular Disorders Research (16 papers)Muscle Physiology and Disorders (11 papers)RNA modifications and cancer (9 papers)
Cited by: Genetics Molecular Biology
Journals: Neurology Clinical Infectious Diseases Molecular Therapy
Partner nations: United States Canada France

In The Last Decade

Samiah Al-Zaidy

26 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Current Clinical Applications of In Vivo Gene Therapy with AAVs

2020 483 citations Jerry R. Mendell, Samiah Al-Zaidy et al. Molecular Therapy profile →
Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy

2020 264 citations Jerry R. Mendell, Zarife Sahenk et al. JAMA Neurology profile →
Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy

2021 173 citations Jerry R. Mendell, Samiah Al-Zaidy et al. JAMA Neurology profile →

Peers

Countries citing papers authored by Samiah Al-Zaidy

Since Specialization

Citations

This map shows the geographic impact of Samiah Al-Zaidy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samiah Al-Zaidy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samiah Al-Zaidy more than expected).

Fields of papers citing papers by Samiah Al-Zaidy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samiah Al-Zaidy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samiah Al-Zaidy. The network helps show where Samiah Al-Zaidy may publish in the future.

Co-authorship network of co-authors of Samiah Al-Zaidy

This figure shows the co-authorship network connecting the top 25 collaborators of Samiah Al-Zaidy. A scholar is included among the top collaborators of Samiah Al-Zaidy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samiah Al-Zaidy. Samiah Al-Zaidy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Validation of high-sensitivity assays to quantitate cerebrospinal fluid and serum β-galactosidase activity in patients with GM1-gangliosidosis 2024 ·Molecular Therapy — Methods & Clinical Development ·(unknown),Catherine E. Vrentas,(unknown),(unknown),Christian Hinderer,David A. Weinstein,Samiah Al-Zaidy,Susan Browne,James M. Wilson,(unknown)	3
2	Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophybreakdown → 2021 ·JAMA Neurology ·Jerry R. Mendell,Samiah Al-Zaidy,Kelly J. Lehman,Markus McColly,Linda Lowes,Lindsay N. Alfano,Natalie F. Reash,M. Iammarino,(unknown),A. de Kleyn,Matthew N. Meriggioli,Richard Shell	173
3	Current Clinical Applications of In Vivo Gene Therapy with AAVsbreakdown → 2020 ·Molecular Therapy ·Jerry R. Mendell,Samiah Al-Zaidy,Louise R. Rodino‐Klapac,Kimberly Goodspeed,Steven J. Gray,Christine N. Kay,Sanford L. Boye,Sanford L. Boye,Lindsey A. George,Stephanie Salabarria,Manuela Corti,Barry J. Byrne,Jacques P. Tremblay	483
4	Duchenne and Becker muscular dystrophy carriers: Evidence of cardiomyopathy by exercise and cardiac MRI testing 2020 ·International Journal of Cardiology ·May Ling Mah,Linda Cripe,(unknown),Samiah Al-Zaidy,(unknown),Kelly J. Lehman,Jamie L. Jackson,M. Iammarino,N. Miller,Jerry R. Mendell,Kan N. Hor	14
5	Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophybreakdown → 2020 ·JAMA Neurology ·Jerry R. Mendell,Zarife Sahenk,Kelly J. Lehman,(unknown),Linda Lowes,N. Miller,M. Iammarino,Lindsay N. Alfano,(unknown),Samiah Al-Zaidy,Sarah Lewis,Kathleen Church,Richard Shell,Linda Cripe,Rachael A. Potter,Danielle A. Griffin,Eric R. Pozsgai,A. Dugar,Mark Hogan,Louise R. Rodino‐Klapac	264
6	AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort 2019 ·Journal of Neuromuscular Diseases ·Samiah Al-Zaidy,Stephen J. Kolb,Linda Lowes,Lindsay N. Alfano,Richard Shell,(unknown),Sukumar Nagendran,Douglas M. Sproule,Douglas E. Feltner,Courtney Wells,Francis G. Ogrinc,Melissa Menier,James L’Italien,W. David Arnold,John T. Kissel,Brian K. Kaspar,Jerry R. Mendell	128
7	From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1 2019 ·Pediatric Neurology ·Samiah Al-Zaidy,Jerry R. Mendell	130
8	Impact of Age and Motor Function in a Phase 1/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement Therapy 2019 ·Pediatric Neurology ·Linda Lowes,Lindsay N. Alfano,W. David Arnold,Richard Shell,Thomas W. Prior,Markus McColly,Kelly J. Lehman,Kathleen Church,Douglas M. Sproule,Sukumar Nagendran,Melissa Menier,Douglas E. Feltner,Courtney Wells,John T. Kissel,Samiah Al-Zaidy,Jerry R. Mendell	133
9	Gene Delivery for Limb-Girdle Muscular Dystrophy Type 2D by Isolated Limb Infusion 2019 ·Human Gene Therapy ·Jerry R. Mendell,Louis G. Chicoine,Samiah Al-Zaidy,Zarife Sahenk,Kelly J. Lehman,Linda Lowes,N. Miller,Lindsay N. Alfano,(unknown),Sarah Lewis,Darren Murrey,(unknown),Danielle A. Griffin,Kathleen Church,John P. Cheatham,John P. Cheatham,Mark Hogan,Louise R. Rodino‐Klapac	37
10	AVXS-101 Phase 1 Gene Replacement Therapy Clinical Trial in SMA Type 1: Patients Treated Early with the Proposed Therapeutic Dose Were Able to Sit Unassisted at a Younger Age (S29.002) 2018 ·Neurology ·Lindsay N. Alfano,Linda Lowes,Samiah Al-Zaidy,Richard Shell,W. David Arnold,Louise R. Rodino‐Klapac,Thomas W. Prior,Katherine Berry,Kathleen Church,John T. Kissel,Sukumar Nagendran,James L’Italien,Douglas M. Sproule,Courtney Wells,Arthur H.M. Burghes,Kevin D. Foust,Kathrin Meyer,Shibi Likhite,Brian K. Kaspar,Jerry R. Mendell	1
11	AVXS-101 Phase 1 Gene Replacement Therapy Clinical Trial in SMA Type 1: Continued Event Free Survival and Achievement of Developmental Milestones (S29.001) 2018 ·Neurology ·Jerry R. Mendell,Samiah Al-Zaidy,Richard Shell,W. David Arnold,Louise R. Rodino‐Klapac,Thomas W. Prior,Linda Lowes,Lindsay N. Alfano,Katherine Berry,Kathleen Church,John T. Kissel,Sukumar Nagendran,James L’Italien,Douglas M. Sproule,Courtney Wells,Arthur H.M. Burghes,Kevin D. Foust,Kathrin Meyer,Shibi Likhite,Brian K. Kaspar	4
12	Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes 2017 ·Molecular Therapy ·Jerry R. Mendell,Zarife Sahenk,Samiah Al-Zaidy,Louise R. Rodino‐Klapac,Linda Lowes,Lindsay N. Alfano,Katherine Berry,N. Miller,Mehmet E. Yalvaç,Igor Dvorchik,Melissa Moore‐Clingenpeel,Kevin M. Flanigan,Kathleen Church,Kim Shontz,(unknown),Sarah Lewis,Markus McColly,Mark Hogan,Brian K. Kaspar	80
13	AVXS-101 Phase 1 gene therapy clinical trial in SMA Type 1: Event free survival and achievement of developmental milestones 2017 ·European Journal of Paediatric Neurology ·Jerry R. Mendell,Samiah Al-Zaidy,Richard Shell,W. David Arnold,Louise R. Rodino‐Klapac,Thomas W. Prior,Linda Lowes,Lindsay N. Alfano,Katherine Berry,Kathleen Church,John T. Kissel,Sukumar Nagendran,James L’Italien,Douglas M. Sproule,Jessica Cardenas,Arthur H.M. Burghes,Kevin D. Foust,Kathrin Meyer,Shibi Likhite,Brian K. Kaspar	2
14	A Roadmap to Newborn Screening for Duchenne Muscular Dystrophy 2017 ·International Journal of Neonatal Screening ·Samiah Al-Zaidy,Michele A. Lloyd-Puryear,Annie Kennedy,Verónica López,Jerry R. Mendell	12
15	480. Gene Therapy for Spinal Muscular Atrophy Type 1 Shows Potential to Improve Survival and Motor Functional Outcomes 2016 ·Molecular Therapy ·Jerry R. Mendell,Samiah Al-Zaidy,Richard Shell,W. David Arnold,Louise R. Rodino‐Klapac,John T. Kissel,Thomas W. Prior,Carlos J. Miranda,Linda Lowes,Lindsay N. Alfano,Katherine Berry,(unknown),Kathleen Church,Lyndsey Braun,Sarah Corcoran,Kathrin Meyer,Shibi Likhite,Arthur H.M. Burghes,Kevin D. Foust,Brian K. Kaspar	17
16	Follistatin Gene Therapy Improves Ambulation in Becker Muscular Dystrophy 2015 ·Journal of Neuromuscular Diseases ·Samiah Al-Zaidy,Zarife Sahenk,Louise R. Rodino‐Klapac,Brian K. Kaspar,Jerry R. Mendell	36
17	Neurological Complications of PCR-ProvenM. pneumoniaeInfections in Children: Prodromal Illness Duration May Reflect Pathogenetic Mechanism 2015 ·Clinical Infectious Diseases ·Samiah Al-Zaidy,Daune MacGregor,Sanjay Mahant,Susan E. Richardson,Ari Bitnun	39
18	A Phase 1/2a Follistatin Gene Therapy Trial for Becker Muscular Dystrophy 2014 ·Molecular Therapy ·Jerry R. Mendell,Zarife Sahenk,Vinod Malik,Ana M. Gómez,Kevin M. Flanigan,Linda Lowes,Lindsay N. Alfano,Katherine Berry,Eric S. Meadows,Sarah Lewis,Lyndsey Braun,Kim Shontz,(unknown),K. Reed Clark,Xiomara Q. Rosales,Samiah Al-Zaidy,Alessandra Govoni,Louise R. Rodino‐Klapac,Mark Hogan,Brian K. Kaspar	189
19	Gene Therapy for Muscular Dystrophy: Moving the Field Forward 2014 ·Pediatric Neurology ·Samiah Al-Zaidy,Louise R. Rodino‐Klapac,Jerry R. Mendell	30
20	Milder phenotype of congenital muscular dystrophy in a novel POMT1 mutation 2011 ·Muscle & Nerve ·Samiah Al-Zaidy,Berivan Baskin,Cynthia Hawkins,Grace Yoon,Peter N. Ray,Jiri Vajsar	6

About Samiah Al-Zaidy

Samiah Al-Zaidy is a scholar working on Genetics, Molecular Biology and Genetics, having authored 26 papers that have together received 1.8k indexed citations. Recurring topics across this work include Neurogenetic and Muscular Disorders Research (16 papers), Muscle Physiology and Disorders (11 papers) and RNA modifications and cancer (9 papers). The work is most often cited by research in Genetics (614 citations), Genetics (652 citations) and Molecular Biology (1.3k citations). Samiah Al-Zaidy has collaborated with scholars based in United States, Canada and France. Frequent co-authors include Jerry R. Mendell, Louise R. Rodino‐Klapac, Linda Lowes, Lindsay N. Alfano, Jerry R. Mendell, Richard Shell, Kelly J. Lehman, Jacques P. Tremblay, Barry J. Byrne and Christine N. Kay. Their work appears in journals such as Neurology, Clinical Infectious Diseases and Molecular Therapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact